NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $563.16 +13.88 (+2.53%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$567.50 +4.34 (+0.77%) As of 04/17/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get REGN alerts:Sign Up Key Stats Today's Range$545.00▼$564.2150-Day Range$546.39▼$744.8352-Week Range$525.99▼$1,211.20Volume827,663 shsAverage Volume712,904 shsMarket Capitalization$61.57 billionP/E Ratio14.71Dividend Yield0.16%Price Target$963.56Consensus RatingModerate Buy Company OverviewRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More… Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreREGN MarketRank™: Regeneron Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 44th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 17 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.85% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 5.85% in the coming year, from $35.92 to $38.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 14.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 14.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.86.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.34. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.76% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 14.15%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRegeneron Pharmaceuticals has a dividend yield of 0.16%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Regeneron Pharmaceuticals is 2.30%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 2.31% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.Read more about Regeneron Pharmaceuticals' dividend. Sustainability and ESG2.3 / 5Environmental Score-2.69 Percentage of Shares Shorted2.76% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 14.15%, indicating that investor sentiment is improving significantly. News and Social Media4.0 / 5News Sentiment1.16 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 39 news articles for Regeneron Pharmaceuticals this week, compared to 27 articles on an average week.Search Interest31 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat Follows21 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.48% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Stock News HeadlinesRegeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License ApplicationApril 18 at 3:00 PM | globenewswire.comSanofi-Regeneron's Dupixent gets FDA's nod for skin conditionApril 18 at 11:31 AM | reuters.comTrump Orders 'National Digital Asset Stockpile'Trump's Tariff Pause Creates Crypto Gold Rush This opportunity could eclipse them all…April 18, 2025 | Crypto 101 Media (Ad)Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)April 18 at 11:15 AM | globenewswire.comPress Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApril 18 at 11:15 AM | globenewswire.comRegeneron gets FDA acceptance to review expanded label for Eylea HDApril 18 at 1:51 AM | msn.comRegeneron price target lowered to $547 from $575 at BofAApril 18 at 1:51 AM | markets.businessinsider.comRegeneron price target lowered to $150 from $170 at CanaccordApril 18 at 1:51 AM | markets.businessinsider.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $712.33 at the start of the year. Since then, REGN shares have decreased by 20.9% and is now trading at $563.16. View the best growth stocks for 2025 here. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Tuesday, February, 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? Regeneron Pharmaceuticals subsidiaries include Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more. Who are Regeneron Pharmaceuticals' major shareholders? Top institutional investors of Regeneron Pharmaceuticals include GAMMA Investing LLC (0.75%), Assenagon Asset Management S.A. (0.44%), Rhumbline Advisers (0.16%) and GuoLine Advisory Pte Ltd (0.05%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi and N Anthony Coles. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings2/04/2025Record date for 3/20 Dividend2/20/2025Ex-Dividend for 3/20 Dividend2/20/2025Dividend Payable3/20/2025Today4/18/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees11,900Year Founded1988Price Target and Rating Average Stock Price Target$963.56 High Stock Price Target$1,300.00 Low Stock Price Target$150.00 Potential Upside/Downside+71.1%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage26 Analysts Profitability EPS (Most Recent Fiscal Year)$38.28 Trailing P/E Ratio14.71 Forward P/E Ratio15.68 P/E Growth2.34Net Income$4.41 billion Net Margins31.07% Pretax Margin33.66% Return on Equity16.32% Return on Assets12.76% Debt Debt-to-Equity Ratio0.09 Current Ratio4.73 Quick Ratio3.95 Sales & Book Value Annual Sales$14.20 billion Price / Sales4.34 Cash Flow$36.98 per share Price / Cash Flow15.23 Book Value$268.50 per share Price / Book2.10Miscellaneous Outstanding Shares109,325,000Free Float101,147,000Market Cap$61.57 billion OptionableOptionable Beta0.44 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:REGN) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.